Subtitle
Clinical results of active scanning proton therapy for primary liver tumors.
Subtitle
Clinical results of active scanning proton therapy for primary liver tumors.
Proto therapy Time
July 2020
Executive summary
This study reported clinical outcomes of 18 patients including 14 patients with hepatocellular carcinoma (HCC) and 3 patients with intrahepatic cholangiocarcinoma (ICC), treated with active scanning PT. One-year overall survival (OS) was 63%.
A significant correlation between worse OS and patient performance status, vascular invasion, and tumor stage was recorded. One-year local control was 90%. Toxicity was low, with a decrease in Child-Pugh score ⩾2 points detected in one patient. No cases of classic radiation-induced liver disease occurred.
Top cancer treatments
Related contents
Proton Therapy Publication
September 2024
Cost-utility analysis of proton beam therapy for locally advanced esophageal cancer in Japan.
Proton Therapy Publication
September 2024
Particle therapy in gastrointestinal cancer-a narrative review.
Proton Therapy Publication
September 2024
Clinical Outcomes of Proton Beam Therapy for Unresectable Locally Advanced Pancreatic Cancer: A Single-Center Retrospective Study.
Proton Therapy Publication
June 2024
Effectiveness and Safety of Carbon Ion Radiotherapy in Solid Tumors: A Systematic Review and Meta-Analysis.
Proton Therapy Publication
June 2024
Optimizing GRID and Lattice Spatially Fractionated Radiation Therapy: Innovative Strategies for Radioresistant and Bulky Tumor Management.
Proton Therapy Publication
May 2024
PTCOG Gastrointestinal Subcommittee Lower Gastrointestinal Tract Malignancies Consensus Statement.
Proton Therapy Publication
May 2024
Comparing 90-Day Postoperative Mortality After Neoadjuvant Proton-Based Versus Photon-Based Chemoradiotherapy for Esophageal Cancer.
Proton Therapy Publication
May 2024
Proton Beam Radiotherapy as a Curative Alternative to Radiofrequency Ablation for Newly Diagnosed Hepatocellular Carcinoma.
Proton Therapy Publication
May 2024
Hypofractionated Radiotherapy-Related Lymphopenia Is Associated With Worse Survival in Unresectable Intrahepatic Cholangiocarcinoma.